# Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

> **NCT03989466** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Recurrent T-Cell Prolymphocytic Leukemia
- T-Cell Prolymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Alemtuzumab
- **DRUG:** Itacitinib

## Key facts

- **NCT ID:** NCT03989466
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-15
- **Primary completion:** 2024-09-24
- **Final completion:** 2024-09-24
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03989466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03989466, "Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03989466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*